Business
AZN: Year to date and Q3 2021 results
AZN: Year to date and Q3 2021 results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1625S\n AstraZeneca PLC\n 12 November 2021\n \n \n \n \n AstraZeneca PLC\n 12 November 2021 07:00 GMT\n \n Year to date and Q3 2021 results\n \n \n AstraZeneca reinforces its scientific leadership through exceptional\npipeline delivery and the addition of Alexion in the quarter\n \n \n - Total Revenue in the year to date, including Alexion from 21 July 2021, was $25,406m, representing growth of 32% (28% at CER). Total Revenue in the third quarter increased by 50% (48% at CER) to $9,866m\n \n - Excluding the pandemic COVID-19 vaccine, Total Revenue increased 21% (17% at CER) in the year to date to $23,187m, and by 34% (32% at CER) in the quarter to $8,816m\n \n - Eight positive Phase III results since June, with potential to change standard of care in several diseases\n \n - Alexion integration progressing well, creating new opportunities in rare diseases\n \n - Operating Expenses in the quarter reflected the addition of Alexion, as well increased R&D expenses across multiple programs, investment in our COVID-19 medicines, and increased SG&A from pre-launch activities following successful pipeline delivery\n \n - Earnings guidance for the full year is unchanged\n \n In the year to date, AstraZeneca delivered double-digit revenue growth from its Oncology, CVRM1 and R&I2 medicines, and established its Rare Disease capability with the acquisition of Alexion Pharmaceuticals Inc. (Alexion). Rare disease is a high-growth area with rapid innovation and significant unmet medical need.\n \n \n Since June, AstraZeneca has made significant progress with its late-stage pipeline, reporting eight positive Phase III trial results and the approval of Saphnelo (anifrolumab) in the US for the treatment of systemic lupus erythematosus, and Ultomiris in the EU for children and adolescents with paroxysmal nocturnal haemoglobinuria. Enhertu received a Breakthrough Therapy Designation from the US FDA3 following ground‑breaking results from the DESTINY-Breast03 trial. The Company also announced positive results for Lynparza in prostate cancer, Imfinzi plus tremelimumab in liver cancer, Imfinzi in biliary tract cancer, PT027 in asthma, ALXN1840 in Wilson disease, and AZD7442 in COVID-19 prophylaxis and trea...